Targeted Cellular Therapy in Blood Cancers | CTL019 for Leukemia

Hematologist-Oncologist David L. Porter, MD, presents on the pioneering use of CTL-019 (formerly CART-19) at Penn Medicine for adoptive immunotherapy in patients with relapsed or chemotherapy-refractory chronic lymphocytic leukemias (CLL) and acute lymphoblastic leukemias (ALL). To date, CTL-019 is the only therapy to bring about sustained remission for these leukemias in adult patients with refractory disease.


Related Links


August 14, 2014

Created by

Penn Physician VideoLink